Cancer Center

Standard adjuvant treatment for HER2-positive breast cancer patients, following primary surgery for their cancer, is Trastuzumab (Herceptin)–typically used in combination with chemotherapy. However, a new study by researchers at Fox Chase Cancer Center reports that it may be safe to treat these patients with both Trastuzumab and adjuvant radiation therapy.

The study will be presented at the annual meeting of the American Society for Radiation Oncology (ASTRO).

» Read more: Terramed Alliance News Safe To Treat HER2-positive Breast Cancer

Related posts

• Event to benefit cancer relief
• Cancer Concern Center in Point Pleasant Beach offers support, hope
• The Dries Cancer Diet: A Practical Guide to the Use of Fresh Fruit and Raw Vegetables in the Treatment of Cancer
• The Richardson Cancer Prevention Diet: A Nutrition and Diet Regimen for the Prevention of Cancer
• Andrew Lloyd Webber urges men to get cancer tests